首页 | 本学科首页   官方微博 | 高级检索  
     


Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label,randomised, phase 3 trial
Authors:Peter R Galle  Richard S Finn  Shukui Qin  Masafumi Ikeda  Andrew X Zhu  Tae-You Kim  Masatoshi Kudo  Valeriy Breder  Philippe Merle  Ahmed Kaseb  Daneng Li  Sohail Mulla  Wendy Verret  Derek-Zhen Xu  Sairy Hernandez  Beiying Ding  Juan Liu  Chen Huang  Michel Ducreux
Affiliation:1. Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany;2. Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, Geffen School of Medicine at University of California, Los Angeles, CA, USA;3. People''s Liberation Army Cancer Center, Jinling Hospital, Nanjing, China;4. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Centre Hospital East, Kashiwa, Japan;5. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA;6. Jiahui International Cancer Center, Jiahui Health, Shanghai, China;7. Department of Hematology and Medical Oncology, Seoul National University College of Medicine, Seoul, South Korea;8. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan;9. Department of Chemotherapy, N N Blokhin National Medical Research Center of Oncology, Moscow, Russia;10. Department of Hepatology and Gastroenterology, Hospital La Croix-Rousse, Lyon, France;11. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;12. Department of Medical Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA;13. Product Development Biometrics, Hoffmann-La Roche, Mississauga, ON, Canada;14. Product Development Oncology, Genentech, San Francisco, CA, USA;15. United States Medical Affairs, Genentech, San Francisco, CA, USA;p. Product Development Oncology, Roche Product Development, Shanghai, China;q. Product Development Biometrics, Roche Product Development, Shanghai, China;r. Safety Science Oncology, Roche Product Development, Shanghai, China;s. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;t. Department of Oncology, National Taiwan University Cancer Centre, Taipei, Taiwan;u. Department of Medical Oncology, Gustave Roussy, Villejuif, France
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号